LeadArtis discloses the IMAB project funded by the CDTI´s Excellence initiative

04-09-2016

LeadArtis announces the initiation of the IMAB project (Cancer immunotherapy with bispecific antibodies) funded by the Centre for Industrial Technology Development (CDTI) under the recently launched PID Excellence Program. The CDTI’s Project Excellence driver acknowledges highly regarded technologies and provides with top financing conditions.

LeadArtis leads the cancer immunotherapy with bispecific costimulatory antibodies (IBIMAB) project

02-09-2016

LeadArtis is proud to announce its participation as coordinator of the IBIMAB project (Cancer immunotherapy with bispecific costimulatory antibodies) funded by the Spanish Ministry of Economy and Competitiveness (MINECO) under the RETOS 2016 Collaboration program. IBIMAB counts with collaborators such as the internationally regarded research institutions: Centro de Investigación Médica Aplicada-CIMA (Pamplona, Spain), Hospital Universitario Puerta de Hierro-HUPH (Madrid, Spain) and Instituto de investigaciones biomédicas Alberto Sols-IIBm-CSIC (Madrid, Spain).

Leadartis to present at BioSpain 2016 in Bilbao

25-08-2016

Leadartis will participate in BioSpain 2016 to be held in Bilbao, Spain (September 28-30th). BioSpain was chosen to present our business to the investment community since is the most important biotechnology event in Spain and one of the most important internationally. LeadArtis will announce its business strategy at the highly regarded investment forum.

LeadArtis discloses a new strategy for making multispecific antibodies with controlled antigen binding domain orientation in the prestigious journal Scientific Reports (Nature publishing group).

01-07-2016

In collaboration with prominent academic institutions (Aarhus University, CIC bioGUNE, Parc de Recerca Biomèdica and Molecular Immunology Unit, Hospital Universitario Puerta de Hierro), LeadArtis´scientists have developed a new approach to generate mono and multispecific antibodies by fusing single-domain antibodies from camelid heavy-chain-only immunoglobulins (VHHs) to the human collagen XVIII trimerization domain (TIEXVIII).

LeadArtis awarded with a RIS3 grant from the Comunidad Autónoma de Madrid in recognition of its highly innovative R&D activity.

08-03-2016

The Ministry of Economy and Finance of the Community of Madrid (MEFCAM), following the recommendations of the European Union, has established the regional strategy for research and innovation for smart specialization of the Community of Madrid framework (hereinafter RIS3) to support the development of highly specialized innovating companies with a requirement of permanent competitiveness.

LeadArtis participates in the second IACT update meeting as well as in the “Immunostimulatory monoclonal antibodies and immunomodulation: harvesting the crop“ international symposium

01-11-2015

The second IACT assessment meeting took place during November 20-21, 2015 in Pamplona, Spain. LeadArtis is a partner of the Immunostimulatory Agonist Antibodies for Cancer Therapy, a 6.9M€ funding consortium which incorporates long-standing expertise in agonist immunostimulatory antibodies (IS-Abs) from research institutions and small-medium enterprises (SEM) in five European countries (Germany, Italy, Spain, Sweden and United Kingdom).

The IACT project (FP7) website is up and running

07-09-2015

LeadArtis is a partner of the IACT (Immunostimulatory Agonist Antibodies for Cancer Therapy) 6.9M€ funding consortium (Project Number: 602262). The IACT is an interdisciplinary platform that involves a total of 10 partners with long-standing expertise in agonist immunostimulatory antibodies (IS-Abs), from research institutions and small-medium enterprises (SEM) located in five European countries (Germany, Italy, Spain, Sweden and United Kingdom).

Escherichia coli offers short-cut to large-scale Trimerbody® manufacturing

05-08-2015

Trimerbody® is a unique mono/multispecific antibody format based on the use of specific collagen trimerization domains and optimized peptide linkers. Trimerbodies are trimeric in solution and exhibit excellent antigen binding capacity and stability in vitro and in vivo.

LeadArtis participates in the first IACT scientific update meeting

15-01-2015

The first IACT review meeting took place on November 17-18, 2014 in Frankfurt, Germany. Representatives of all partners, including management and scientific teams participated in the assembly.

Leadartis announces its partnership in the TERET project.

28-10-2014

Leadartis is proud to announce its participation as a partner in the TERET project (New Treatments for Degenerative Retina Diseases) funded by the Spanish Ministry of Economy and Competitiveness (MINECO) under the RETOS of the society program. The MINECO’s participation demonstrates its support of Leadartis technology research and main objectives.

Syndicate content

Latest News

LeadArtis to present at the final Chemostart pitching initiative in recognition of its highly innovative R&D activity
31-01-2019
The Chemostart initiative (sponsored by the Chemo company) launched in 2018 as a call for...
LeadArtis project finalist of the Kaertor and J&J innovation award in recognition of its highly innovative R&D activity
08-11-2018
The Kærtor Foundation together with Janssen (a Johnson & Johnson company) launched in 2018...
Leadartis discloses the project: ATTACK-Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes
11-12-2018

LeadArtis is pleased to announce its participation as coordinator of the ATTACK project (Cancer...